(601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 601607 · · 23 pages · Chinese
Shanghai Pharmaceuticals Holding Co. Ltd. on 6ix
Earlier from Shanghai Pharmaceuticals
- (601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Progress of Drug Clinical Trials
- (601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
- (601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Approval for Production of Clevidipine Emulsion Injection
- (601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Transfer of Equity Interests in Zeus Investment Limited and Its Affiliates
- (601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Annual Operating Performance Assessment and Compensation Plan for Senior Executives
Later from Shanghai Pharmaceuticals
- (601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Completion of Private Investment Fund Filing for the SIIC Biomedical Industry Private Fund Established with the Company's Participation
- (601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Receipt of Clinical Trial Approval Notice for Treprostinil Diethanolamine Inhalation Powder
- (601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Shareholding Increase Plan of Controlling Shareholder
Follow Shanghai Pharmaceuticals into a list and get an email when it puts out news.
Follow Shanghai Pharmaceuticals